liu.seSearch for publications in DiVA
Change search
Link to record
Permanent link

Direct link
BETA
Bisgin, Atil
Publications (3 of 3) Show all publications
Celik, B., Didem Yalcin, A., Bisgin, A., Dimitrakopoulou-Strauss, A., Kargi, A. & Strauss, L. G. (2013). Level of TNF-related apoptosis-inducing-ligand and CXCL8 correlated with 2-[18F]Fluoro-2-deoxy-D-glucose uptake in anti-VEGF treated colon cancers. Medical Science Monitor, 19, 875-882
Open this publication in new window or tab >>Level of TNF-related apoptosis-inducing-ligand and CXCL8 correlated with 2-[18F]Fluoro-2-deoxy-D-glucose uptake in anti-VEGF treated colon cancers
Show others...
2013 (English)In: Medical Science Monitor, ISSN 1234-1010, E-ISSN 1643-3750, Vol. 19, p. 875-882Article in journal (Refereed) Published
Abstract [en]

Background

The changes and correlations of TRAIL (TNF-related apoptosis-inducing-ligand) and CXCL8 (IL8) prior to treatment and three months following therapy as well as the corresponding Positron emission tomography (PET/CT) (SUVmax: standardized uptake maximum values) results were evaluated.

Material/Methods

The measurements were taken before and after treatment for comparison purposes. The study population comprised 29 patients with Metastatic Colorectal cancer (MCRC), undergoing PET/CT scanning prior to treatment.

Results

There were significant changes prior to treatment and three months later for sTRAIL (p=0.0080) and CXCL8 (p=0.0001)values. Generally, sTRAIL values were increasing during therapy, while a decrease was observed for CXCL8. Correlation analysis was applied to the data and revealed significant correlations for the SUVmax in the primary tumor prior to treatment and CXCL8 prior to therapy (p=0.0303). Furthermore, significant correlations were observed for the SUVmax and sTRAIL (p=0.0237) as well as CXCL8 (p=0.0002) three months after treatment initiation. CXCL8 prior to treatment was also correlated with the SUV three months after onset of treatment (p=0.0072). A significant correlation was noted for one combination of two variables, the SUVmax in the metastases and CXCL8 prior to treatment (p=0.0175). These results are supported when we group the SUVmax in the metastases following treatment into two groups with SUVmax <5 and SUVmax >5.

Conclusions

This study provides evidence that proteomics patterns of sTRAIL and CXCL8 predict tumor response und survival in MCRC patients treated with bevacizumab and within a high concordance of FDG-PET/CT findings.

Place, publisher, year, edition, pages
Medical Science International, 2013
Keywords
metastatic colorectal cancer (MCRC), CXCL8 (IL8), soluble TRAIL (sTRAIL), anti VEGF antibody (Bevacizumab), F-18-Deoxyglucose positron emission tomography (FDG-PET/CT), proteomics study, (SUVmax: standardized uptake maximum values)
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-100477 (URN)10.12659/MSM.889605 (DOI)000325846300001 ()24145180 (PubMedID)
Available from: 2013-11-08 Created: 2013-11-08 Last updated: 2017-12-06Bibliographically approved
Yalcin, A. D., Bisgin, A. & Gorczynski, R. M. (2012). IL-8, IL-10, TGF-beta, and GCSF Levels Were Increased in Severe Persistent Allergic Asthma Patients with the Anti-IgE Treatment. Mediators of Inflammation (720976)
Open this publication in new window or tab >>IL-8, IL-10, TGF-beta, and GCSF Levels Were Increased in Severe Persistent Allergic Asthma Patients with the Anti-IgE Treatment
2012 (English)In: Mediators of Inflammation, ISSN 0962-9351, E-ISSN 1466-1861, no 720976Article in journal (Refereed) Published
Abstract [en]

Background. Allergic asthma is showed an increase in Th2-cytokine and IgE levels and an accumulation activation of Th2 cells, eosinophils and mast cells. However, recent studies focused on cell-based mechanisms for the pathogenesis of allergic asthma. Objectives. In this study, we compare the anti-IgE treatment modality in the dynamics of immune system cytokine levels in severe persistent asthma (SPA) patients who had no other any allergic disease, newly diagnosed allergic asthma patients and healthy volunteers. Study Design. The study population consisted of 14 SPA patients, 14 newly diagnosed allergic asthma patients and 14 healthy volunteers included as controls. Cytokine levels were measured. Total and specific IgE levels of anti-IgE monoclonal antibody treated patients, serum high-sensitivity C-reactive protein (hsCRP) levels, FEV1/FVC rates and asthma control test (ACT) were measured for the clinical follow-up. Results. We observed that SPA patients presented increasing levels of IL-8, IL-10, TGF-beta and GCSF during the anti-IgE treatment in period of sampling times at 4 months and 18 months. However this increase was not correlated neither with serum hsCRP levels nor FEV1/FVC rates. Conclusions. Our study gives a different perspective for the SPA and anti-IgE immunotherapy efficacy at the cell cytokine-linked step.

Place, publisher, year, edition, pages
Hindawi Publishing Corporation, 2012
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:liu:diva-87968 (URN)10.1155/2012/720976 (DOI)000312847600001 ()
Available from: 2013-01-28 Created: 2013-01-28 Last updated: 2017-12-06
Yalcin, A. D., Gumuslu, S., Parlak, G. E. & Bisgin, A. (2012). Soluble trail as a marker of efficacy of allergen-specific immunotherapy in patients with allergic rhinoconjunctivitis. Medical Science Monitor, 18(10), CR617-CR621
Open this publication in new window or tab >>Soluble trail as a marker of efficacy of allergen-specific immunotherapy in patients with allergic rhinoconjunctivitis
2012 (English)In: Medical Science Monitor, ISSN 1234-1010, E-ISSN 1643-3750, Vol. 18, no 10, p. CR617-CR621Article in journal (Refereed) Published
Abstract [en]

BACKGROUND:

Allergic rhinitis is a common health problem affecting the immune system. The homeostasis of the immune system is regulated by apoptosis. In this study, serum circulating soluble TRAIL levels of allergic rhinoconjunctivitis patients before and after allergen-specific immunotherapy were evaluated.

MATERIAL/METHODS:

The sTRAIL levels of pre- and post-treated allergic rhinoconjunctivitis patients (n=25) were compared to age- and sex-matched healthy individuals (n=25). sTRAIL levels were measured by ELISA. The skin prick test (SPT) results were recorded before and after treatment.

RESULTS:

The sTRAIL levels between the pre-treated and control groups were significantly different (p<0.0001). However, there was no significant difference between the post-treated group and healthy individuals (p=0,801). SPT was a statistically significant difference between the values of the research group before and after immunotherapy (grasses mixture, barley mixture, Oleaauropeae, D. Pteronyssinus, D. farinae).

CONCLUSIONS:

The sTRAIL levels were decreased after allergen-specific immunotherapy to healthy levels and may be of use as a marker of efficacy of immunotherapy in allergic rhinoconjunctivitis patients.

Place, publisher, year, edition, pages
Medical Science International Publishing, 2012
Keywords
allergen-specific immunotherapy; sTRAIL levels; allergic rhinitis; skin prick test
National Category
Social Sciences
Identifiers
urn:nbn:se:liu:diva-87230 (URN)10.12659/MSM.883488 (DOI)000311590200013 ()
Available from: 2013-01-14 Created: 2013-01-14 Last updated: 2017-12-06
Organisations

Search in DiVA

Show all publications